Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.
Aurobindo has filed its first inhaled product in the US, amid speculation that the generic could be a rival to Teva's Qvar (beclomethasone dipropionate), used to treat asthma.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
